COMMUNIQUÉS West-GlobeNewswire

Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update
06/11/2018
Net cash used in operating and investing activities was $33.7 million in the third quarter and $7.5 million in the first nine months of 2018; quarter-end cash and restricted cash position of $455.6 million provides [...]
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
06/11/2018
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced today that Pablo J. [...]
iCAD to Report Third Quarter and Nine Months Ended September 30, 2018 Financial Results on Tuesday, November 13th
06/11/2018
NASHUA, N.H., Nov. 06, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial [...]
Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
SAN FRANCISCO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis ( [...]
SeaSpine Reports Third Quarter 2018 Financial Results
06/11/2018
CARLSBAD, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results
06/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the third quarter ended September 30, 2018. “ [...]
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2018
06/11/2018
RANCHO CUCAMONGA, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018, after [...]
CytomX Therapeutics Announces Third Quarter 2018 Financial Results
06/11/2018
ESMO Presentations Support CX-072 Product Profile and Probody™ Proof-of-Concept Advancement of Clinical Stage Probody Drug Conjugate Programs, CX-2009 and CX-2029 CX-188 IND Filing Marks Fifth Probody Therapeutic to [...]
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
06/11/2018
DURHAM, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that the management team will present a company overview at four upcoming investor conferences: On Tuesday, [...]
Athersys Reports Third Quarter 2018 Results
06/11/2018
Management to host conference call at 4:30pm EST today CLEVELAND, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended September 30, 2018. Highlights [...]
Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates
06/11/2018
- Merger completed; now operating as Aravive, Inc. (Nasdaq:ARAV), a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics - FDA Fast Track designation granted for lead candidate, AVB-S6-500 [...]
Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results
06/11/2018
Total First-Quarter Revenues of $202.3 Million, Up 13 Percent First-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 Percent Revised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted [...]
Zafgen to Present at the Stifel 2018 Healthcare Conference
06/11/2018
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
Cutera Reports Third Quarter 2018 Financial Results
06/11/2018
truSculpt® iD Sets Company Record for New System Launch Company Achieves Sequential Gross Margin Improvement BRISBANE, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), [...]
Aptose Reports Results for the Third Quarter Ended September 30, 2018
06/11/2018
Conference call is scheduled for tomorrow, Wednesday, November 7 th at 8:00 AM ET SAN DIEGO and TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a [...]
Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
06/11/2018
--NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI -- -- SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne vulgaris -- -- Company planning for a February 2019 [...]
Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
06/11/2018
Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, [...]
Principia Biopharma Reports Third Quarter Financial Results
06/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with [...]
Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology [...]

Pages